Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT05120960 |
Title | A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain Tumors |
Recruitment | Withdrawn |
Gender | both |
Phase | Phase I |
Variant Requirements | No |
Sponsors | M.D. Anderson Cancer Center |
Indications | |
Therapies | |
Age Groups: | adult | senior |
Covered Countries |